ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.363,24
1,37%
S&P 500
5.726,48
0,14%
US Dollar vs BRL
5,4574
-1,45%
Bitcoin
63.720,20
0,62%
Brent Oil
74,595
1,17%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Notícias

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:LSE:HCM
DataHoraFonteTítuloCódigoCompanhia
24/09/202404:49Alliance NewsAlliance NewsTakeda Pharmaceutical says Fruzaqla cancer drug gets Japan backingLSE:HCMHutchmed (china) Limited
24/09/202404:00RNS Regulatory NewsHutchmed (China) Limited Japan Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
09/09/202403:00RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at ESMO and WCLCLSE:HCMHutchmed (china) Limited
30/08/202408:24Alliance NewsAlliance NewsHutchmed "disappointed" as it withdraws fruquintinib applicationLSE:HCMHutchmed (china) Limited
30/08/202405:30RNS Regulatory NewsHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
30/08/202403:00RNS Regulatory NewsHutchmed (China) Limited Update on Fruquintinib for Gastric Cancer in ChinaLSE:HCMHutchmed (china) Limited
22/08/202405:30RNS Regulatory NewsHutchmed (China) Limited Standard form for notification of major holdingsLSE:HCMHutchmed (china) Limited
21/08/202405:30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED to Host Expert Call to discuss ITPLSE:HCMHutchmed (china) Limited
06/08/202406:00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
31/07/202410:41Alliance NewsAlliance NewsHutchmed confident of full year guidance for oncology and immunologyLSE:HCMHutchmed (china) Limited
31/07/202408:00RNS Regulatory NewsHutchmed (China) Limited 2024 Interim Results and Business UpdatesLSE:HCMHutchmed (china) Limited
05/07/202415:08Alliance NewsAlliance NewsIN BRIEF: Hutchmed's tazemetostat given priority review in ChinaLSE:HCMHutchmed (china) Limited
04/07/202403:00RNS Non-RegulatoryHutchmed (China) Limited NDA Acceptance in China for TazemetostatLSE:HCMHutchmed (china) Limited
28/06/202408:35RNS Non-RegulatoryHutchmed (China) Limited Overseas Regulatory Announcement: Form F-3 FilingLSE:HCMHutchmed (china) Limited
28/06/202405:30RNS Regulatory NewsHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
26/06/202405:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2024 HY Financial ResultsLSE:HCMHutchmed (china) Limited
24/06/202406:30RNS Non-RegulatoryHutchmed (China) Limited Save the Date: HUTCHMED to Present R&D UpdatesLSE:HCMHutchmed (china) Limited
24/06/202406:00Alliance NewsAlliance NewsIN BRIEF: Hutchmed China notes Takeda obtains EU approval for FruzaqlaLSE:HCMHutchmed (china) Limited
24/06/202403:00RNS Regulatory NewsHutchmed (China) Limited European Commission Approval for FRUZAQLALSE:HCMHutchmed (china) Limited
17/06/202406:32Alliance NewsAlliance NewsHutchmed celebrates "promising" results for sovleplenib in ChinaLSE:HCMHutchmed (china) Limited
17/06/202403:00RNS Non-RegulatoryHutchmed (China) Limited Lancet Publish Phase III ESLIM-01 ResultsLSE:HCMHutchmed (china) Limited
07/06/202414:13Alliance NewsAlliance NewsIN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506LSE:HCMHutchmed (china) Limited
07/06/202403:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase I Trial of HMPL-506LSE:HCMHutchmed (china) Limited
03/06/202403:00RNS Non-RegulatoryHutchmed (China) Limited Nature Medicine Publish Phase III FRUTIGA ResultsLSE:HCMHutchmed (china) Limited
24/05/202403:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Presentations at 2024 ASCO Annual MeetingLSE:HCMHutchmed (china) Limited
17/05/202413:58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
17/05/202411:00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
17/05/202403:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
14/05/202410:33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
14/05/202403:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
 Apresentando as notícias mais relevantes sobre:LSE:HCM

Seu Histórico Recente

BOV
MMAQ4
Minasmaquinas PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados